Our Therapies

ARANESP® Therapy

Violet Health Outpatient Specialty Infusion Care

About ARANESP® Therapy

ARANESP® (darbepoetin alfa) is an erythropoiesis-stimulating agent, usually shortened to ESA. It can be given as a small injection just under the skin or directly into a vein, and Violet Health provides both. It treats anemia, a shortage of red blood cells, in two very different groups of patients: people living with chronic kidney disease, and adults receiving chemotherapy that suppresses the bone marrow.

Erythropoietin is a hormone your kidneys make to tell your bone marrow to produce red blood cells. When the kidneys are damaged, or when chemotherapy suppresses the marrow, that signal falls short and anemia follows. Darbepoetin alfa is a laboratory-made version of that hormone, engineered with two extra carbohydrate chains so it stays in the body roughly three times longer than epoetin alfa. That longer life is the practical difference, and it is why ARANESP® can be given weekly, every two weeks, or in some cases every three or four weeks rather than several times a week.

A useful contrast. Most of the medicines described on our other pages act on the immune system or on the tumor itself. ARANESP® does neither. It replaces a hormone signal your body is no longer producing in sufficient amounts, so it treats a consequence of your illness rather than the illness.

ARANESP® carries a boxed warning, and it shapes every dosing decision. Erythropoiesis-stimulating agents increase the risk of death, heart attack, stroke, heart failure, blood clots in the veins, clotting of dialysis vascular access, and, in people with cancer, tumor progression or recurrence. The response to that risk is not to avoid the medicine but to use the smallest dose that keeps you from needing a blood transfusion. Everything below follows from that principle.

The goal is not a normal hemoglobin. This surprises many patients. Treatment is started when hemoglobin is below 10 g/dL, and the dose is reduced or held when it approaches or exceeds 11 g/dL in patients on dialysis, or exceeds 10 g/dL in patients not on dialysis. No clinical trial has identified a hemoglobin target, a dose, or a dosing strategy that does not carry the added cardiovascular risk, so the aim is to avoid transfusion rather than to normalize the blood count.

Dosing in chronic kidney disease. Adults typically start at 0.45 mcg/kg once weekly, given into a vein or under the skin. Adults who are not on dialysis may instead start at 0.75 mcg/kg every two weeks. Children 1 month and older on dialysis start at 0.45 mcg/kg weekly, and children 1 year and older who are not on dialysis may receive 0.75 mcg/kg every two weeks. For patients on hemodialysis the intravenous route is recommended. If you are switching from epoetin alfa, your starting dose is calculated from your previous weekly dose rather than from your weight.

Dosing alongside chemotherapy. Adults receiving myelosuppressive chemotherapy receive either 2.25 mcg/kg under the skin once weekly or a flat 500 mcg under the skin every three weeks. The flat every-three-week option is the only dose on this page that is not based on weight. Treatment begins only when hemoglobin is below 10 g/dL and at least two more months of chemotherapy are planned, and it stops when that course of chemotherapy is finished.

There is a response checkpoint at eight weeks. In chemotherapy-related anemia, if your transfusion needs have not fallen and your hemoglobin has not risen after eight weeks of treatment, ARANESP® is stopped rather than continued at a higher dose. Dose increases are also not made more often than once every four weeks, because hemoglobin responds slowly and a rapid rise is the pattern associated with the risks in the boxed warning.

Iron comes first. ARANESP® cannot build red blood cells without enough iron to make them from. Your iron stores are checked before you start and regularly during treatment, and most patients need supplemental iron, taken by mouth or given into a vein, to keep transferrin saturation at 20% or above and ferritin at 100 ng/mL or above. Other treatable causes of anemia, including vitamin B12 or folate deficiency, bleeding, and hemolysis, are corrected or ruled out first, since an ESA will not work around them.

When ARANESP® is not given at all. It is contraindicated in uncontrolled high blood pressure, in anyone who has developed pure red cell aplasia after treatment with ARANESP® or another erythropoietin product, and in anyone with a serious allergic reaction to darbepoetin alfa. The multiple-dose vials contain benzyl alcohol and are not used in newborns, infants, pregnant women, or nursing mothers.

How it is supplied and given. ARANESP® comes as a single-dose prefilled syringe or vial. It is never shaken, never diluted, and never mixed with another medicine in the same syringe. The dose is the same whether it is given under the skin or into a vein, so your provider chooses the route that fits your situation. Violet Health administers ARANESP® both ways: as a subcutaneous injection in the abdomen, upper arm, or thigh, or as an intravenous push through a peripheral line or existing port. Either visit takes only a few minutes. Patients on hemodialysis may also receive it during a dialysis session through their existing access.

Conditions treated by this therapy

ARANESP® is FDA-approved for people who are:

Adults with anemia due to chronic kidney disease who are receiving dialysis
Adults with anemia due to chronic kidney disease who are not on dialysis, when hemoglobin is below 10 g/dL and falling in a way that makes a transfusion likely
Children 1 month and older with anemia due to chronic kidney disease who are receiving dialysis
Children 1 year and older with anemia due to chronic kidney disease who are not on dialysis
Adults with anemia caused by chemotherapy that suppresses the bone marrow, given for a non-myeloid cancer, when at least two additional months of chemotherapy are planned

Important limitations of use. This label is unusually specific about when ARANESP® should not be used, and a referral that falls outside these boundaries cannot be filled. It is not indicated for patients receiving chemotherapy when the expected outcome of treatment is cure. It is not indicated when anemia from chemotherapy can be managed with transfusion. It is not indicated for patients receiving hormonal therapy, biologic products, or radiation therapy unless they are also receiving myelosuppressive chemotherapy. It is not a substitute for a transfusion when anemia needs to be corrected immediately. And it has not been shown to improve quality of life, fatigue, or general well-being.

A note on myelodysplastic syndromes. ARANESP® is not FDA-approved for anemia due to myelodysplastic syndromes. Patients with transfusion-dependent anemia in lower-risk MDS who have already tried an erythropoiesis-stimulating agent are treated differently, and our RYTELO™ page describes that pathway.

A note on other causes of anemia. Before treatment starts, iron deficiency, vitamin B12 and folate deficiency, bleeding, hemolysis, inflammation, and underlying blood disorders are evaluated and corrected where possible. An ESA is appropriate only once those have been addressed.

Your nephrologist or oncologist will confirm whether this therapy is right for you before treatment begins.

ARANESP® Price

The cost of prescription medications can vary depending on your insurance coverage. If you're concerned about the price of your medication:

Contact your insurance provider to understand your coverage
Ask your doctor or pharmacist about lower-cost alternatives
Check with the drug manufacturer about financial assistance programs
Explore patient assistance options if you're uninsured or underinsured

Remember, many resources exist to help patients access necessary medications. Don't hesitate to ask for help if you're struggling with medication costs. No patient should go without necessary treatment due to financial limitations. If you have questions about financial assistance opportunities, contact a member of our Violet Health team.

What to Expect During ARANESP® Therapy

When you arrive at a Violet Health location, our team will greet you by name and help you settle into a private, welcoming space. ARANESP® visits are short, and here is what a typical one looks like. Your care team will:

Check your blood pressure at every visit, since high blood pressure is the most common side effect and uncontrolled hypertension is a reason to hold the dose
Review your most recent hemoglobin, which is checked weekly until it is stable and at least monthly after that, because the result decides whether your dose stays the same, drops, or is held
Confirm your iron studies are current and that any iron therapy you have been prescribed is underway
Ask specifically about chest pain, new shortness of breath, pain or swelling in a leg, weakness on one side of the body, trouble speaking, or sudden vision change, since clotting events are what this medicine is monitored for
Confirm your current weight, since every dose except the flat 500 mcg every-three-week option is calculated from it, and children’s doses change as they grow
Give the dose by the route your specialist has chosen — a quick injection just under the skin, rotating the site between the abdomen, thigh, and upper outer arm, or an intravenous push through a peripheral line or your existing port. Violet Health provides both.
Stay with you and watch you for a short period afterward, since an allergic reaction, though uncommon, would show itself early
Protect your privacy and comfort throughout the visit

Plan for a short visit. The injection itself takes moments, and most patients are in and out within 20 to 45 minutes once check-in, a blood pressure check, and a brief observation period are included. There is no premedication and no sedation, so most patients drive themselves. The visit length is about the same whichever route you receive; an intravenous dose adds only the time to place a small peripheral line if you do not have a port.

If you are on hemodialysis, your nephrologist may prefer to give ARANESP® through your dialysis access during a session you were attending anyway, in which case you may not need a separate visit with us. If your specialist orders the intravenous route and you are not on dialysis, or your dialysis center does not administer it, Violet Health can give it intravenously at any of our locations.

Your rhythm depends on why you are being treated. Patients with kidney disease generally come weekly or every two weeks at first, and some move to a longer interval once hemoglobin is stable. Patients receiving chemotherapy come weekly, or every three weeks if they are on the flat 500 mcg dose, and often align the visit with a chemotherapy appointment.

Expect frequent lab draws early on. Hemoglobin is the number your dose is built around, so it is measured weekly until it settles. Iron studies are repeated during treatment as well. This eases considerably once you are stable.

Improvement is deliberately slow. Red blood cells take time to make, so hemoglobin rises over weeks rather than days, and most people notice less fatigue and breathlessness gradually. The slowness is intentional. A rapid rise is the pattern linked to the cardiovascular risks in the boxed warning, which is why doses are not increased more often than once every four weeks and are cut by around a quarter to 40% if hemoglobin climbs more than 1 g/dL in a two-week period.

Treatment can be held, and that is normal. If your hemoglobin rises above the level needed to avoid transfusion, your dose is reduced or paused and then restarted at a lower dose once it falls back. A held dose is a sign the medicine is working, not a setback.

When treatment ends. For chemotherapy-related anemia, ARANESP® stops when your course of chemotherapy is complete, since the cause of the anemia has gone. For kidney disease it is usually an ongoing therapy, continuing as long as your hemoglobin needs the support.

ARANESP® Side Effects

Most people tolerate the injection itself well. The considerations that matter here are cardiovascular rather than the nausea, rash, and infusion reactions described on our other pages, and they are the reason the dose is kept as low as it can be.

In chronic kidney disease, the most common side effects were:

High blood pressure, which is the most frequently reported reaction
Shortness of breath and cough
Swelling in the legs, ankles, or feet
Low blood pressure during a dialysis session

In patients receiving chemotherapy, the most common were: abdominal pain, swelling, and clotting events in the veins. The picture here is shaped as much by the chemotherapy as by ARANESP®, so your oncology team will help separate the two.

Injection site reactions. Redness, swelling, warmth, or itching where the needle went in is common with any subcutaneous medicine. Reactions are usually mild, settle within a day or two, and are less likely if the site is rotated each time. Tell your nurse if a site becomes painful, hardens, or does not clear.

ARANESP® carries a boxed warning. Please read this section carefully. These are the risks that the lowest-effective-dose approach is designed to limit.

Death, heart attack, stroke, heart failure, and blood clots: in kidney disease trials, patients treated toward a hemoglobin above 11 g/dL had more of these events than patients treated toward a lower target. No target, dose, or strategy has been found that avoids the added risk.
Clotting of dialysis vascular access: a fistula or graft is more likely to clot on an ESA. Tell your dialysis team immediately if the usual thrill or bruit over your access changes or disappears.
Shortened survival and faster tumor growth in cancer: ESAs shortened overall survival, increased tumor progression, or increased recurrence in studies of breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. This is why the medicine is used only for anemia caused by myelosuppressive chemotherapy, is never used when the goal of treatment is cure, and is stopped when the chemotherapy course ends.

Although less common, other serious side effects can occur. Please alert our clinical staff or seek medical attention immediately if you experience any of the following:

A blood clot: pain, swelling, warmth, or redness in a leg or arm, or sudden shortness of breath, chest pain that worsens with a deep breath, or coughing up blood. Clots in the legs and lungs are the ones reported most often.
A heart attack or stroke: chest pressure or pain, pain spreading to the arm or jaw, sudden weakness or numbness on one side of the body, drooping of the face, confusion, trouble speaking, or loss of vision. Call emergency services rather than our office.
Severe or rising blood pressure: a severe headache that is new for you, confusion, or a sudden sharp rise in your home readings. Very high pressure can cause brain swelling and seizures. Blood pressure is controlled before treatment starts, checked at every visit, and ARANESP® is held if it is not controlled.
Seizures: seizures have occurred in patients on ESAs, most often in the first several months. Tell us about any seizure history before you start, and do not drive if you have had one.
Pure red cell aplasia: a sudden loss of response to the medicine with worsening tiredness and a hemoglobin that falls despite treatment. The body makes antibodies that neutralize both the medicine and its natural counterpart, so the marrow stops producing red cells. It can appear after weeks or after years. If it is confirmed, ARANESP® is stopped permanently and no other erythropoietin product is given.
A serious allergic reaction: hives, wheezing, trouble breathing, or swelling of the face, lips, or tongue. Seek emergency care immediately.
A severe skin reaction: a blistering or peeling rash, painful sores in the mouth, eyes, or genitals, or skin that sheds in sheets. Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with ESAs. Treatment is stopped and not restarted.

Good to know: there are no immune-mediated warnings here. ARANESP® does not stimulate the immune system the way the checkpoint inhibitors on our other pages do, so there is no watch list of inflamed organs, no steroid protocol, and no premedication. Adjustments are made by lowering, holding, or stopping the dose based on your hemoglobin, never by treating through a rising count.

Pregnancy and breastfeeding. There is not enough information to know whether ARANESP® harms an unborn baby, and the label does not set a contraception window, which is a notable difference from the cancer medicines on our other pages where three to 12 months is typical. What does matter is the formulation: multiple-dose vials contain benzyl alcohol and are not used in pregnancy, while nursing, or in newborns and infants, so a single-dose presentation is chosen instead. Tell your care team if you are pregnant, planning a pregnancy, or breastfeeding.

Information to Include With Referral

Eligibility for ARANESP® depends on a specific hemoglobin threshold, on the cause of the anemia, and on what has already been ruled out, so referrals need more laboratory detail than most. Including the following helps us schedule the right appointment the first time:

The indication being treated: chronic kidney disease on dialysis, chronic kidney disease not on dialysis, or anemia caused by myelosuppressive chemotherapy
The most recent hemoglobin with the date it was drawn, plus the trend over recent weeks, since treatment begins only below 10 g/dL
Dialysis status, modality, session schedule, and type of vascular access, since access clotting is a specific risk and the intravenous route is preferred for hemodialysis patients
Estimated GFR and recent kidney function for patients not on dialysis
Iron studies, specifically transferrin saturation and ferritin, along with any oral or intravenous iron already prescribed
Vitamin B12, folate, reticulocyte count, and the results of any workup for bleeding, hemolysis, or an underlying blood disorder
Transfusion history, with dates and units, since avoiding transfusion is the goal that defines the dose
Prior erythropoiesis-stimulating agent exposure, including epoetin alfa or a biosimilar, the dose and schedule used, and how the patient responded, since a switch is dosed from the previous weekly dose rather than from weight
Any history of pure red cell aplasia or of antibodies to an erythropoietin product, since that is a contraindication rather than a caution
Recent blood pressure readings and current antihypertensive medicines, with confirmation that hypertension is controlled, since uncontrolled hypertension is also a contraindication
Cardiovascular history including heart attack, stroke, heart failure, deep vein thrombosis, or pulmonary embolism, plus any anticoagulation in use
Any seizure history, and whether surgery is planned, since perioperative clotting risk is a consideration
For oncology referrals, the tumor type with confirmation that it is non-myeloid, the chemotherapy regimen, how many months of chemotherapy remain, and explicit confirmation that the goal of treatment is not cure
For pediatric referrals, age and weight, since the minimum age differs depending on whether the child is on dialysis
Current weight with the date it was taken, plus the intended dose, route, and interval
Any known hypersensitivity to darbepoetin alfa or to an excipient
Pregnancy, breastfeeding, or planned pregnancy status, since the benzyl alcohol in multiple-dose vials makes a single-dose presentation necessary